IPSC SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Century Therapeutics Presents Nonclinical Data for CNTY-813 at EASD 2026 and Outlines Clinical Timeline for Type 1 Diabetes Cell Therapy

Oct 2, 2026

8-K

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Sep 9, 2026

8-K

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Aug 12, 2026

8-K

Century Therapeutics Announces Transition of Chief Scientific Officer to Part-Time Role

Jun 16, 2026

8-K

Century Therapeutics, Inc. Announces Results of 2026 Annual Meeting and Approval of Authorized Share Increase

Jun 12, 2026

8-K

Century Therapeutics Presents Positive Preclinical Data for CNTY-813 Type 1 Diabetes Therapy

Jun 8, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B7

SHARE RESALE REGISTRATION | Shares: 176,086,947

May 21, 2026

424B5

[No Baby Shelf]* March 2026 ATM | Offering amount: $131,619,741 | Bank: TD Cowen

Mar 26, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 7,868,666

Jun 26, 2024

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 15,873,011

May 22, 2024

424B4

Common Stock-

Jun 21, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 12, 2026

S-3

SHARE RESALE REGISTRATION

Feb 5, 2026

S-3/A

July 2025 SHELF

Jan 5, 2026

S-3

July 2025 SHELF EFFECTIVE, DATED 2026-01-09

Jul 10, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 20, 2025

S-3

SHARE RESALE REGISTRATION | Shares amount: 7,868,666 EFFECTIVE

Jun 18, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 16, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Dec 2, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Dec 2, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Nov 21, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Carr Douglas (Reporting)

Nov 5, 2026

144

Form 144 - Report of proposed sale of securities

Nov 3, 2026

Russotti Gregory (Reporting)

Sep 15, 2026

Carr Douglas (Reporting)

Sep 15, 2026

Pfeiffenberger Brent (Reporting)

Sep 15, 2026

144

Form 144 - Report of proposed sale of securities

Sep 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 18, 2026

LETTER

Form UPLOAD - SEC-generated letter

Feb 17, 2026

CORRESP

Form CORRESP - Correspondence

Feb 17, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 12, 2026

CORRESP

Form CORRESP - Correspondence

Jan 7, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jul 14, 2025

Century Therapeutics, Inc. IPSC · SEC Filings